Cargando…

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade

BACKGROUND: Late-stage or recurrent intrahepatic cholangiocarcinoma (ICC) patients exhibit poor prognosis due to limited sensitivity to chemotherapy or radiotherapy and coexistence of multiple lesions. Programmed cell death protein 1 (PD-1) blockade provides a therapeutic opportunity for patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoliang, Yao, Jianfei, Song, Lele, Zhang, Sujing, Huang, Tanxiao, Li, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683483/ https://www.ncbi.nlm.nih.gov/pubmed/31383016 http://dx.doi.org/10.1186/s40425-019-0692-z

Ejemplares similares

PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
por: Yang, Jiabao, et al.
Publicado: (2023)

Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report
por: Liu, Yan, et al.
Publicado: (2023)

Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer
por: Lin, Haishan, et al.
Publicado: (2022)

Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report
por: He, Yanxin, et al.
Publicado: (2021)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
por: Wang, Ting, et al.
Publicado: (2023)

Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report
por: Cheng, Xianshuo, et al.
Publicado: (2023)

Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report
por: Zhong, Liting, et al.
Publicado: (2022)

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
por: Ding, Yuwei, et al.
Publicado: (2023)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
por: Gou, Miaomiao, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma
por: Mahadevan, Anand, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
por: Fontugne, Jacqueline, et al.
Publicado: (2017)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma
por: Gkika, Eleni, et al.
Publicado: (2017)

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma
por: Sandler, Kiri A., et al.
Publicado: (2016)

Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria
por: Sun, Ci-Yuan, et al.
Publicado: (2020)

Gene Expression Profile Reveals a Prognostic Signature of Non–MSI-H/pMMR Colorectal Cancer
por: Liu, Zaoqu, et al.
Publicado: (2022)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer
por: Zhou, Pu, et al.
Publicado: (2023)

Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021)

Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4(+) T Cells in the Central Region of pMMR CRC
por: Qi, Jingwen, et al.
Publicado: (2021)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
por: Zhu, Jiangpeng, et al.
Publicado: (2023)

PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells
por: Gutting, Tobias, et al.
Publicado: (2021)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
por: Liao, Chun-Xu, et al.
Publicado: (2023)

Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors
por: Zhang, Yan, et al.
Publicado: (2022)

Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors
por: Lu, Jia-Cheng, et al.
Publicado: (2019)

Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma
por: Kim, Jun Won, et al.
Publicado: (2021)

The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model
por: Klawitter, Moritz, et al.
Publicado: (2022)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2022)

Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
por: Zhang, Ze, et al.
Publicado: (2021)

Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers
por: Zhang, Jun, et al.
Publicado: (2020)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
por: Liu, Ze-Long, et al.
Publicado: (2020)

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
por: Yang, Hui, et al.
Publicado: (2022)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice
por: Wabitsch, Simon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ddvffv89olb6qt055mvkpqvr36